Lifezoom Launches Veyra Series: Flexible Red Light Therapy Panels That Redefine Home Wellness
NEW YORK, July 17, 2025 /PRNewswire/ -- Lifezoom, a pioneer of red light therapy in the USA, is excited to expand with the new industry-leading Veyra Series, red light therapy panels that mix creativity, adaptability, and health-focused design. Now, with two launch products, Veyra C and Veyra S, this versatile red light technology, built on a flexible silicone base material,...
Co-PSMA trial: Recruitment successfully completed
SYDNEY, July 17, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT06907641) Investigator-Initiated Trial (IIT) led by Prof Louise Emmett at St Vincent's Hospital...
RapidClaims Receives Frost & Sullivan’s 2025 North American Healthcare IT-Software and Services Technology Innovation Leadership Recognition for Excellence in AI-Driven RCM Automation
Recognized for driving operational efficiency and accelerating customer acquisition through AI-powered automation and a highly adaptive deployment model SAN ANTONIO, July 17, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to announce that RapidClaims has been recognized with the 2025 North American Healthcare IT-Software and Services Technology Innovation Leadership Recognition in the healthcare IT industry for its outstanding achievements in product...
SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate
Company aims for technology advancement and platform expansion with Korea's first influenza vaccine using an adjuvant Interim results from the Phase 1/2 trial expected by 2027, aimed at entering the high-immunogenicity vaccine market "Our SKYCellflu platform with our adjuvanted vaccine experience will lay a strong foundation for future success." SEONGNAM, South...
Five-year Pharmacovigilance study by NTC confirms safety of fixed-dose eye drops for Post-cataract Surgery
MILAN, July 17, 2025 /PRNewswire/ -- A recently published five-year pharmacovigilance study confirms the excellent safety profile of a fixed-dose combination eye drop containing an anti-inflammatory steroid and a quinolone antibiotic, developed by NTC, indicated for the prevention and treatment of inflammation and prevention of infection following cataract surgery in adults. The study was submitted when nearly 4 million...
SpaceGut Marks World Microbiome Day with Science-Backed Solution for Malaysia’s Obesity Issue
KUALA LUMPUR, Malaysia, July 17, 2025 /PRNewswire/ -- In celebration of World Microbiome Day, SpaceGut, a Malaysia-based health tech company, introduces a scientific and personalised approach to one of the country's most pressing health concerns, obesity. Through its Gut Microbiome Test Kit and AI-powered personalised meal plan, SpaceGut aims to address the root microbial imbalances that contribute to excessive...
Vietnam’s Dairy Pride: Vinamilk Makes Headlines at Growth Asia Summit with 6-HMO Breakthrough
SINGAPORE, July 17, 2025 /PRNewswire/ -- At the Growth Asia Summit 2025, which took place from July 15–17 in Singapore, Vinamilk was honored to be the only Vietnamese company invited as a keynote speaker. The Growth Asia Summit is the largest forum for growth opportunities in the food, beverage, and nutrition industries in Asia. The brand made a remarkable...
GC Biopharma Receives Marketing Authorization for BARYCELA in Vietnam
YONGIN, South Korea, July 17, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean pharmaceutical company, announced that its varicella vaccine BARYCELA has received marketing authorization from the Drug Administration of Vietnam (DAV). Following domestic approval in 2020 and WHO Pre-Qualification (PQ) in 2023, GC Biopharma has been accelerating individual country registrations...
Total Investment of Approx. USD 7.3 Million in Malaria and TB R&D Projects With Partners Including European Vaccine Initiative, University of Copenhagen, and University of Tübingen
TOKYO, July 17, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1 billion (USD 7.3 million1) in four R&D projects for the development of vaccine, drug, and diagnostics for malaria and tuberculosis (TB).2 Investment of JPY 800 million (USD 5.5 million1) in malaria vaccine project Malaria is a serious infectious...
Unlocking New Opportunities in Asia and the Greater Bay Area
SHANGHAI, July 17, 2025 /PRNewswire/ -- CPHI & PMEC China 2025 concluded in June with a record-breaking 109,056 attendees, fostering meaningful connections across the entire pharmaceutical supply chain. This remarkable success is a testament to the strong demand within China's thriving pharma industry. Building on this momentum, CPHI & PMEC Shenzhen 2025 will take place from 1-3 September 2025 at...
